0001104659-23-128806.txt : 20231222 0001104659-23-128806.hdr.sgml : 20231222 20231222161527 ACCESSION NUMBER: 0001104659-23-128806 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231222 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 231509974 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 8-K 1 tm2333600d1_8k.htm FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2023

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey

08830

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (609) 619-3990

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On December 22, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fourth fiscal quarter and year ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated December 22, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.

Date: December 22, 2023	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Chief Financial Officer

EX-99.1 2 tm2333600d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU

	·	Commencement of ONS-5010 NORSE EIGHT clinical trial targeted for first calendar quarter of 2024
	·	Company reaffirms potential for European approval for ONS-5010 with Marketing Authorization Application (MAA) decision date anticipated in the first half of 2024
	·	Resubmission of the ONS-5010 Biologics License Application (BLA) expected by the end of calendar year 2024

ISELIN, N.J., December 22, 2023 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve U.S. Food and Drug Administration (FDA) approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced recent corporate highlights and financial results for its fiscal year ended September 30, 2023.

“We remain committed to working with the FDA to design and undertake the additional clinical study for ONS-5010 that, if successful, will satisfy the FDA’s requirements for approval,” commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics. “The patient need for an ophthalmic approved bevacizumab remains and we are steadfast in our mission to meet this need.”

Upcoming Anticipated Milestones

	·	FDA response on NORSE EIGHT Special Protocol Assessment (SPA) in early February 2024;
	·	Commencement of NORSE EIGHT expected in first calendar quarter of 2024;
	·	MAA decision date in the EU for ONS-5010 expected targeted for first half of 2024;
	·	Completion of NORSE EIGHT in the U.S. anticipated in 2024; and
	·	Resubmission of the ONS-5010 BLA expected by the end of calendar year 2024.

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Regulatory Update

As previously announced, following a Type A meeting with the FDA held in October 2023, the FDA informed Outlook Therapeutics that it can conduct a non-inferiority study evaluating ONS-5010 versus ranibizumab in a 3-month study of treatment naïve patients with a primary efficacy endpoint at 2 months. Subsequently, as discussed with and recommended by the FDA, Outlook Therapeutics submitted a clinical trial protocol and requested a Type A meeting with the FDA for feedback. The FDA has already provided written feedback on the protocol, which Outlook Therapeutics has incorporated. The revised protocol is the subject of the SPA request, in which Outlook Therapeutics is seeking further confirmation from the FDA that NORSE EIGHT, if successful, addresses the FDA’s requirement for a second adequate and well-controlled clinical trial to support the resubmission of the ONS-5010 BLA for wet AMD. The FDA is expected to provide a response to the SPA by early February 2024.

NORSE EIGHT will be a randomized, controlled, parallel-group, masked study of neovascular age-related macular degeneration subjects randomized in a 1:1 ratio to receive 1.25 mg ONS-5010 or 0.5 mg ranibizumab intravitreal injections. Subjects will receive injections at Day 0 (randomization), Week 4, and Week 8 visits. Approximately 400 patients are expected to be enrolled in the study.

Additionally, the Company previously announced that it submitted an MAA in Europe, which was validated for review in December 2022. The formal review process of the MAA by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is underway with an estimated decision date expected in the first half of 2024. In addition to pursuing potential strategic partnering opportunities in the EU and other regions, such as the current partnership with Syntone Biopharma JV in China, Outlook Therapeutics is also exploring potential expanded relationships with Cencora (formerly AmerisourceBergen) to support the launch of ONS-5010 in international markets.

If approved, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) will be the first FDA approved ophthalmic formulation of bevacizumab.

Financial Highlights for the 2023 Fiscal Year Ended September 30, 2023

For the fiscal year ended September 30, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of $59.0 million, or $0.24 per basic and diluted share, compared to a net loss attributable to common stockholders of $66.1 million, or $0.31 per basic and diluted share, for the prior fiscal year.

As of September 30, 2023, Outlook Therapeutics had cash and cash equivalents of $23.4 million. On December 21, 2023, Outlook Therapeutics reached an agreement with the holder of its outstanding convertible promissory note to extend the maturity until April 1, 2024.

About ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no FDA-approved ophthalmic formulations of bevacizumab are available currently, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 would provide an FDA-approved option for physicians that currently prescribe unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for the treatment of wet AMD.

Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to achieve FDA approval for the launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; the FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, Outlook Therapeutics and Cencora entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States. For more information, please visit www.outlooktherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “optimistic,” “plan,” “potential,” “target,” “will,” or “would” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010’s potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg, expectations concerning our ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including with respect to an additional clinical trial and CMC issues, expectations concerning the NORSE EIGHT trial design, the timing for initiation and completion of NORSE EIGHT and resubmission of the BLA for ONS-5010, expectations concerning decisions of regulatory bodies, including the FDA and EMA, and the timing thereof, plans for potential commercial launch of ONS-5010, expectations concerning the relationship with Cencora and the benefits and potential expansion thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by the FDA, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the “SEC”), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, to be filed with the SEC, and future quarterly reports we file with the SEC, which include uncertainty of future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflict, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Investor Inquiries:

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247

OTLK@jtcir.com

# # #

Outlook Therapeutics, Inc.

Consolidated Statements of Operations

(Amounts in thousands, except per share data)

		Year ended September 30,
		2023				2022
Operating expenses:
Research and development		$	26,453			$	42,331
General and administrative			26,673				20,740
			53,126				63,071
Loss from operations			(53,126	)			(63,071	)
Loss on equity method investment			11				49
Interest expense, net			1,560				1,487
Loss on extinguishment of debt			578				1,025
Change in fair value of promissory notes			3,756				883
Change in fair value of warrant liability			(51	)			(466	)
Loss before income taxes			(58,980	)			(66,049	)
Income tax expense			3				3
Net loss attributable to common stockholders		$	(58,983	)		$	(66,052	)

Per share information:
Net loss per share of common stock, basic and diluted		$	(0.24	)		$	(0.31	)
Weighted average shares outstanding, basic and diluted			250,177				212,079

Consolidated Balance Sheet Data

(Amounts in thousands)

		September 30,
		2023				2022
Cash and cash equivalents		$	23,392			$	17,397
Total assets		$	32,301			$	28,528
Current liabilities		$	46,732			$	19,730
Total stockholders' (deficit) equity		$	(14,438	)		$	8,737

EX-101.SCH 3 otlk-20231222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 otlk-20231222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Series A Warrants EX-101.PRE 5 otlk-20231222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 22, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 22, 2023
Entity File Number	001-37759
Entity Registrant Name	Outlook Therapeutics, Inc.
Entity Central Index Key	0001649989
Entity Tax Identification Number	38-3982704
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	485 Route 1 South
Entity Address, Address Line Two	Building F
Entity Address, Address Line Three	Suite 320
Entity Address, City or Town	Iselin
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08830
City Area Code	609
Local Phone Number	619-3990
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	OTLK
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2333600d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001649989 2023-12-22 2023-12-22 iso4217:USD shares iso4217:USD shares false 0001649989 8-K 2023-12-22 Outlook Therapeutics, Inc. DE 001-37759 38-3982704 485 Route 1 South Building F Suite 320 Iselin NJ 08830 609 619-3990 false false false false Common Stock OTLK NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://outlooktherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports otlk-20231222.xsd otlk-20231222_lab.xml otlk-20231222_pre.xml tm2333600d1_8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333600d1_8k.htm": { "nsprefix": "otlk", "nsuri": "http://outlooktherapeutics.com/20231222", "dts": { "schema": { "local": [ "otlk-20231222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "otlk-20231222_lab.xml" ] }, "presentationLink": { "local": [ "otlk-20231222_pre.xml" ] }, "inline": { "local": [ "tm2333600d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://outlooktherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333600d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333600d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentRegistrationStatement", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentTransitionReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "NoTradingSymbolFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentDescription", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodStartDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentQuarterlyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12gTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAccountingStandard", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityVoluntaryFilers", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Extension", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentAnnualReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine3", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentShellCompanyReport", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityReportingObligation", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitySmallBusiness", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCountry", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFilerCategory", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityPrimarySicNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AnnualInformationForm", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityShellCompany", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CountryRegion", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://outlooktherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-128806-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-128806-xbrl.zip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end